查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2111103

人工智慧驅動的神經發育篩檢市場預測至2034年：按篩檢類型、技術、實施方法、年齡層、最終用戶和地區分類的全球分析

AI-Based Neurodevelopment Screening Market Forecasts to 2034 - Global Analysis By Screening Type, Technology, Screening Mode, Age Group, End User, and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球人工智慧驅動的神經發育篩檢市場預計將在 2026 年達到 28 億美元，並在預測期內以 20.7% 的複合年成長率成長，到 2034 年達到 126 億美元。

人工智慧驅動的神經發育篩檢是指利用人工智慧和機器學習技術來識別神經發育障礙的早期徵兆，例如泛自閉症障礙、注意力不足過動症（ADHD）、言語和語言障礙以及發展遲緩。這些解決方案分析行為模式、面部表情、言語、動作、眼動追蹤和問卷數據，以支持快速、客觀和準確的篩檢。人工智慧驅動的神經發育篩檢能夠實現早期干預，提高臨床效率，並方便獲得評估服務。人們對兒童早期發育的日益關注以及數位健康技術的進步正在推動人工智慧驅動的神經發育篩檢解決方案在全球範圍內的應用。

擴大早期兒童篩檢計劃

人工智慧驅動的神經發育篩檢解決方案透過分析行為、發展、語言和認知指標，幫助早期發現神經發育障礙。這些方案能夠幫助臨床醫生、教育工作者和看護者更早發現潛在的發展問題。各國政府和醫療機構正在擴大幼兒的發展篩檢計畫。早期療育策略在改善長期發展結果的重要性日益凸顯。人工智慧的進步正在提升數位篩檢工具的準確性和易用性。這些因素正在加速醫療和教育領域對這些工具的市場應用。

取得檢驗資料集的困難

為了使人工智慧模型能夠提供可靠的篩檢結果，多樣化且高品質的臨床資料集至關重要。標準化且具代表性的發展資料的取得受限會降低模型的準確性和泛化能力。診斷標準的差異進一步加劇了資料集建構的複雜性。資料收集通常需要豐富的臨床經驗和長期的檢驗。這些挑戰阻礙了可靠的人工智慧篩檢系統的發展。提高數據品質仍然是實現廣泛市場應用的關鍵。

校內數位篩檢項目

數位篩檢平台使學校能夠透過結構化評估和人工智慧分析，有效地識別學生的發展問題。早期發現有助於及時轉診至專科醫生，並採取適當的教育介入措施。學校正擴大採用技術驅動的篩檢來改善對學生的支援服務。醫療機構和教育機構之間的合作也不斷拓展。數位化平台也有助於改善醫療和教育資源匱乏地區的可近性。預計這一趨勢將為解決方案供應商帶來巨大的成長機會。

人工智慧預測模型中的偏差

基於有限或不平衡資料集訓練的人工智慧系統，其篩檢結果在不同人群中可能存在差異。此類偏差會影響篩檢的可靠性和臨床信心。開發者必須不斷提高模型的透明度和公正性。監管機構日益重視負責任的人工智慧開發。持續檢驗對於確保篩檢結果的公正性至關重要。解決演算法偏差問題仍將是該行業的關鍵優先事項。

新型冠狀病毒（COVID-19）的影響：

新冠疫情加速了數位神經發育篩檢的普及，因為面對面的臨床評估受到限制。醫療機構擴大利用遠距評估平台來維持兒童發展篩檢服務。在醫療服務受限期間，家庭也更熟悉用於早期發展評估的數位化工具。遠端醫療的整合在疫情期間顯著擴展。即使在醫療服務恢復正常後，數位篩檢解決方案的使用率仍持續成長。

在預測期內，自閉症篩檢領域預計將佔據最大的市場佔有率。

泛自閉症障礙是目前使用人工智慧驅動的行為和發展評估工具篩檢最廣泛的神經發育障礙，因此，預計在預測期內，自閉症篩檢領域將佔據最大的市場佔有率。早期發現有助於及時進行臨床評估和製定乾預計劃。醫療機構正擴大採用數位自閉症篩檢解決方案來提高診斷效率。人工智慧演算法的不斷改進正在提升篩檢的準確性。

在預測期內，家庭篩檢細分市場預計將呈現最高的複合年成長率。

在預測期內，居家篩檢領域預計將呈現最高的成長率，這主要得益於家長對便捷易用的發展評估工具的需求不斷成長，這些工具可以在醫療機構之外進行。人工智慧驅動的數位平台支援持續監測，同時減少了對面對面就診的依賴。智慧型手機應用程式和基於雲端的評估工具正變得越來越普及。家長意識的提高也進一步推動了早期發展篩檢的發展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其完善的早期兒童保健計劃。美國憑藉著人工智慧驅動的兒童篩檢技術的廣泛應用引領市場，而加拿大則在其醫療保健系統中推廣數位化發育評估計畫。墨西哥在數位化醫療現代化的支持下，正逐步加大兒童健康篩檢的投入。強大的臨床研究能力和先進的醫療基礎設施將繼續鞏固其市場領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於兒童醫療服務的擴張。中國正投資人工智慧驅動的兒童醫療項目，印度正透過數位健康舉措加強早期發展篩檢，日本持續推動兒童診斷技術，韓國則在發育醫學領域拓展人工智慧的應用。人們對早期診斷意識的提高以及醫療數位化進程的推進，正支撐著該地區的強勁成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球人工智慧驅動的神經發育篩檢市場：按篩檢類型分類

  • 自閉症篩檢
  • ADHD篩檢
  • 學習障礙篩檢
  • 發展遲緩篩檢
  • 其他類型的篩檢

第6章：全球人工智慧驅動的神經發育篩檢市場：按技術分類

  • 機器學習
  • 電腦視覺
  • 自然語言處理
  • 預測分析
  • 其他技術

第7章：全球人工智慧驅動的神經發育篩檢市場：依篩檢方法分類

  • 在醫療機構的實施
  • 遠端篩檢
  • 學校篩檢
  • 家庭篩檢
  • 其他篩檢方法

第8章：全球人工智慧驅動的神經發育篩檢市場：按年齡層分類

  • 嬰兒
  • 嬰兒
  • 孩子們
  • 青春期

第9章：全球人工智慧驅動的神經發育篩檢市場：按最終用戶分類

  • 兒童醫院
  • 診斷中心
  • 學校
  • 早期療育中心
  • 其他最終用戶

第10章：全球人工智慧驅動的神經發育篩檢市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Cognoa, Inc.
  • EarlyBird AI
  • LinusBio Inc.
  • Qbtech AB
  • CogniFit Ltd.
  • Cambridge Cognition Ltd.
  • Philips Healthcare
  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Medtronic plc
  • Natus Medical Incorporated
  • EMOTIV Inc.
  • Neuroelectrics SL
  • BrainCheck, Inc.
  • Compumedics Limited
Product Code: SMRC38804

According to Stratistics MRC, the Global AI-Based Neurodevelopment Screening Market is accounted for $2.8 billion in 2026 and is expected to reach $12.6 billion by 2034 growing at a CAGR of 20.7% during the forecast period. AI-based neurodevelopment screening refers to the use of artificial intelligence and machine learning technologies to identify early signs of neurodevelopmental conditions such as autism spectrum disorder, ADHD, speech and language disorders, and developmental delays. These solutions analyze behavioral patterns, facial expressions, speech, movement, eye tracking, and questionnaire data to support rapid, objective, and accurate screening. AI-based neurodevelopment screening enables earlier intervention, improves clinical efficiency, and enhances accessibility to assessment services. Increasing awareness of early childhood development and advancements in digital health technologies are driving the adoption of AI-based neurodevelopment screening solutions worldwide.

Market Dynamics:

Driver:

Increasing early childhood screening initiatives

AI-based neurodevelopment screening solutions analyze behavioral, developmental, speech, and cognitive indicators to support the early identification of neurodevelopmental conditions. They help clinicians, educators, and caregivers detect potential developmental concerns at an earlier stage. Governments and healthcare organizations are expanding developmental screening programs for young children. Early intervention strategies are gaining greater importance in improving long-term developmental outcomes. Advances in artificial intelligence are enhancing the accuracy and accessibility of digital screening tools. These factors are accelerating market adoption across healthcare and educational settings.

Restraint:

Limited availability of validated datasets

Artificial intelligence models require diverse, high-quality clinical datasets to deliver reliable screening outcomes. Limited access to standardized and representative developmental data can reduce model accuracy and generalizability. Variations in diagnostic criteria further complicate dataset development. Data collection often requires significant clinical expertise and long-term validation. These challenges slow the development of highly reliable AI screening systems. Improving data quality remains essential for broader market adoption.

Opportunity:

School-based digital screening programs

Digital screening platforms enable schools to identify developmental concerns efficiently through structured assessments and AI-assisted analysis. Early identification supports timely referrals and appropriate educational interventions. Schools are increasingly adopting technology-enabled screening to improve student support services. Collaboration between healthcare providers and educational institutions is expanding. Digital platforms also improve accessibility in underserved communities. This trend is expected to create substantial growth opportunities for solution providers.

Threat:

Bias in AI prediction models

AI systems trained on limited or unbalanced datasets may produce inconsistent screening results across different populations. Such biases can affect screening reliability and clinical confidence. Developers must continuously improve model transparency and fairness. Regulatory authorities are placing greater emphasis on responsible AI development. Ongoing validation is necessary to ensure equitable screening performance. Addressing algorithmic bias will remain a critical priority for the industry.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of digital neurodevelopment screening as in-person clinical assessments became more limited. Healthcare providers increasingly used remote assessment platforms to maintain developmental screening services for children. Families also became more comfortable using digital tools for early developmental evaluation during periods of restricted healthcare access. Telehealth integration expanded significantly during the pandemic. Digital screening solutions continued gaining acceptance after healthcare services normalized.

The autism screening segment is expected to be the largest during the forecast period

The autism screening segment is expected to account for the largest market share during the forecast period as autism spectrum disorder is one of the most widely screened neurodevelopmental conditions using AI-assisted behavioral and developmental assessment tools. Early identification enables timely clinical evaluation and intervention planning. Healthcare providers are increasingly adopting digital autism screening solutions to improve diagnostic efficiency. Continuous improvements in AI algorithms are enhancing screening accuracy.

The home-based screening segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home-based screening segment is predicted to witness the highest growth rate due to growing demand for convenient and accessible developmental assessments that parents can complete outside clinical settings. AI-powered digital platforms support continuous monitoring while reducing dependence on in-person visits. Smartphone applications and cloud-based assessment tools are becoming more widely available. Greater awareness among parents is further encouraging early developmental screening.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong early childhood healthcare programs. The United States leads the market through widespread adoption of AI-driven pediatric screening technologies, while Canada is expanding digital developmental assessment programs across healthcare systems. Mexico is gradually increasing investments in child health screening initiatives supported by digital healthcare modernization. Strong clinical research capabilities and advanced healthcare infrastructure continue supporting market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by expanding pediatric healthcare services. China is investing in AI-powered child healthcare programs, while India is strengthening early developmental screening through digital health initiatives. Japan continues advancing pediatric diagnostic technologies, and South Korea is expanding artificial intelligence applications in developmental healthcare. Rising awareness of early diagnosis and increasing healthcare digitization are supporting strong regional growth.

Key players in the market

Some of the key players in AI-Based Neurodevelopment Screening Market include Cognoa, Inc., EarlyBird AI, LinusBio Inc., Qbtech AB, CogniFit Ltd., Cambridge Cognition Ltd., Philips Healthcare, GE HealthCare Technologies Inc., Siemens Healthineers AG, Medtronic plc, Natus Medical Incorporated, EMOTIV Inc., Neuroelectrics S.L., BrainCheck, Inc. and Compumedics Limited.

Key Developments:

In April 2026, GE HealthCare Technologies Inc. launched an enhanced PET tracer analytics suite designed to quantify tau protein deposition in the brain. The software tool equips clinicians with precise imaging biomarkers to evaluate neurodegenerative disease progression.

In November 2025, Philips Healthcare expanded its neuro-diagnostic ecosystem by embedding quantitative brain-mapping algorithms into its clinical MRI suites. The software measures regional cortical atrophy and microstructural changes to deliver standardized biomarkers for memory loss.

Screening Types Covered:

  • Autism Screening
  • ADHD Screening
  • Learning Disability Screening
  • Developmental Delay Screening
  • Other Screening Types

Technologies Covered:

  • Machine Learning
  • Computer Vision
  • Natural Language Processing
  • Predictive Analytics
  • Other Technologies

Screening Modes Covered:

  • Clinic-Based
  • Remote Screening
  • School-Based Screening
  • Home-Based Screening
  • Other Screening Modes

Age Groups Covered:

  • Infants
  • Toddlers
  • Children
  • Adolescents

End Users Covered:

  • Pediatric Hospitals
  • Diagnostic Centers
  • Schools
  • Early Intervention Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI-Based Neurodevelopment Screening Market, By Screening Type

  • 5.1 Autism Screening
  • 5.2 ADHD Screening
  • 5.3 Learning Disability Screening
  • 5.4 Developmental Delay Screening
  • 5.5 Other Screening Types

6 Global AI-Based Neurodevelopment Screening Market, By Technology

  • 6.1 Machine Learning
  • 6.2 Computer Vision
  • 6.3 Natural Language Processing
  • 6.4 Predictive Analytics
  • 6.5 Other Technologies

7 Global AI-Based Neurodevelopment Screening Market, By Screening Mode

  • 7.1 Clinic-Based
  • 7.2 Remote Screening
  • 7.3 School-Based Screening
  • 7.4 Home-Based Screening
  • 7.5 Other Screening Modes

8 Global AI-Based Neurodevelopment Screening Market, By Age Group

  • 8.1 Infants
  • 8.2 Toddlers
  • 8.3 Children
  • 8.4 Adolescents

9 Global AI-Based Neurodevelopment Screening Market, By End User

  • 9.1 Pediatric Hospitals
  • 9.2 Diagnostic Centers
  • 9.3 Schools
  • 9.4 Early Intervention Centers
  • 9.5 Other End Users

10 Global AI-Based Neurodevelopment Screening Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Cognoa, Inc.
  • 13.2 EarlyBird AI
  • 13.3 LinusBio Inc.
  • 13.4 Qbtech AB
  • 13.5 CogniFit Ltd.
  • 13.6 Cambridge Cognition Ltd.
  • 13.7 Philips Healthcare
  • 13.8 GE HealthCare Technologies Inc.
  • 13.9 Siemens Healthineers AG
  • 13.10 Medtronic plc
  • 13.11 Natus Medical Incorporated
  • 13.12 EMOTIV Inc.
  • 13.13 Neuroelectrics S.L.
  • 13.14 BrainCheck, Inc.
  • 13.15 Compumedics Limited

List of Tables

  • Table 1 Global AI-Based Neurodevelopment Screening Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI-Based Neurodevelopment Screening Market, By Screening Type (2023-2034) ($MN)
  • Table 3 Global AI-Based Neurodevelopment Screening Market, By Autism Screening (2023-2034) ($MN)
  • Table 4 Global AI-Based Neurodevelopment Screening Market, By ADHD Screening (2023-2034) ($MN)
  • Table 5 Global AI-Based Neurodevelopment Screening Market, By Learning Disability Screening (2023-2034) ($MN)
  • Table 6 Global AI-Based Neurodevelopment Screening Market, By Developmental Delay Screening (2023-2034) ($MN)
  • Table 7 Global AI-Based Neurodevelopment Screening Market, By Other Screening Types (2023-2034) ($MN)
  • Table 8 Global AI-Based Neurodevelopment Screening Market, By Technology (2023-2034) ($MN)
  • Table 9 Global AI-Based Neurodevelopment Screening Market, By Machine Learning (2023-2034) ($MN)
  • Table 10 Global AI-Based Neurodevelopment Screening Market, By Computer Vision (2023-2034) ($MN)
  • Table 11 Global AI-Based Neurodevelopment Screening Market, By Natural Language Processing (2023-2034) ($MN)
  • Table 12 Global AI-Based Neurodevelopment Screening Market, By Predictive Analytics (2023-2034) ($MN)
  • Table 13 Global AI-Based Neurodevelopment Screening Market, By Other Technologies (2023-2034) ($MN)
  • Table 14 Global AI-Based Neurodevelopment Screening Market, By Screening Mode (2023-2034) ($MN)
  • Table 15 Global AI-Based Neurodevelopment Screening Market, By Clinic-Based (2023-2034) ($MN)
  • Table 16 Global AI-Based Neurodevelopment Screening Market, By Remote Screening (2023-2034) ($MN)
  • Table 17 Global AI-Based Neurodevelopment Screening Market, By School-Based Screening (2023-2034) ($MN)
  • Table 18 Global AI-Based Neurodevelopment Screening Market, By Home-Based Screening (2023-2034) ($MN)
  • Table 19 Global AI-Based Neurodevelopment Screening Market, By Other Screening Modes (2023-2034) ($MN)
  • Table 20 Global AI-Based Neurodevelopment Screening Market, By Age Group (2023-2034) ($MN)
  • Table 21 Global AI-Based Neurodevelopment Screening Market, By Infants (2023-2034) ($MN)
  • Table 22 Global AI-Based Neurodevelopment Screening Market, By Toddlers (2023-2034) ($MN)
  • Table 23 Global AI-Based Neurodevelopment Screening Market, By Children (2023-2034) ($MN)
  • Table 24 Global AI-Based Neurodevelopment Screening Market, By Adolescents (2023-2034) ($MN)
  • Table 25 Global AI-Based Neurodevelopment Screening Market, By End User (2023-2034) ($MN)
  • Table 26 Global AI-Based Neurodevelopment Screening Market, By Pediatric Hospitals (2023-2034) ($MN)
  • Table 27 Global AI-Based Neurodevelopment Screening Market, By Diagnostic Centers (2023-2034) ($MN)
  • Table 28 Global AI-Based Neurodevelopment Screening Market, By Schools (2023-2034) ($MN)
  • Table 29 Global AI-Based Neurodevelopment Screening Market, By Early Intervention Centers (2023-2034) ($MN)
  • Table 30 Global AI-Based Neurodevelopment Screening Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.